China SXT Pharmaceuticals (SXTC) Current Deferred Revenue (2018 - 2026)

China SXT Pharmaceuticals has reported Current Deferred Revenue for 9 years, with the latest figure at $104423.0 in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 78.11% year-over-year to $104423.0 in Q1 2026; TTM through Mar 2026 was $104423.0, a 78.11% increase from a year earlier, with the FY2026 full-year figure at $104423.0, up 78.11% from the prior year.
• Current Deferred Revenue was $104423.0 for Q1 2026 at China SXT Pharmaceuticals, up from $65057.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $190340.0 in Q3 2024, with the low at $58627.0 in Q1 2025.
• Average Current Deferred Revenue over 5 years is $122700.7, with a median of $104423.0 recorded in 2026.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue plunged 70.23% in 2022, then soared 192.15% in 2023.
• Over 5 years, Current Deferred Revenue stood at $65101.0 in 2022, then jumped by 192.15% to $190193.0 in 2023, then advanced by 0.08% to $190340.0 in 2024, then sank by 65.82% to $65057.0 in 2025, then jumped by 60.51% to $104423.0 in 2026.
• The last three Current Deferred Revenue figures came in at $104423.0 (Q1 2026), $65057.0 (Q3 2025), and $58627.0 (Q1 2025), per Business Quant data.